KZR Kezar Life Sciences, Inc.
USHealthcareAs of 2026-05-11 16:00
Why KZR matters now
Kezar Life Sciences, Inc. (KZR) is a US stock in Healthcare. The latest InvestLog snapshot shows $7.29 with +0.00% on the session and $53.9M in market capitalization; recent performance reads 1-month +0.00% and YTD +15.90%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-5.8M, and EPS of $-0.78. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -78.0%.
The latest indexable market news headline is "HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—KZR, FORA, SLNO, and APLS" from Globe News Wire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $7.00; recent insider activity includes Chiang Pichi Luo filing D-Return. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.82
P/S
0.00
EV/EBITDA
0.35
DCF Value
$9.69
FCF Yield
-78.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-58.4%
ROA
-66.5%
ROIC
-63.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-5.8M | $-0.78 |
| Q4 2025 | $0.00 | $-14.5M | $-1.99 |
| FY 2025 | $0.00 | $-56.0M | $-7.66 |
| Q3 2025 | $0.00 | $-11.2M | $-1.53 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$11.00
Target (Median)
$7.00
Target Range
$5.00 - $21.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.41
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being investigated for its potential in oncology and immunology. The firm was founded in 2015 and is headquartered in South San Francisco, California.